{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Area under the plasma concentration versus time curve from time zero to 24 hours post dosing for M3258.","groups":[{"description":"Participants received M3258 at a dose of 10 mg orally, twice per week until disease progression.","id":"OG000","title":"M3258 10 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 20 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) until disease progression.","id":"OG002","title":"M3258 10 mg QD"}],"populationDescription":"The most participants who had evaluable PK, samples at 24 hour (Day 2) were collected. Therefore, the AUC0-t and AUC0-24 would not differ and AUC0-24 at single dose was not reported. It was also planned to carry the trough value at steady state for QD dosing forward and impute it as trough value at 24 hours. Due to the change from the QD to twice per week dosing this did not apply anymore and AUC0-24 at steady state was not calculated.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8 or Cycle 1 Day 15: Pre-dose 1, 2, 3, 4, 5, 6, and 8 hours post-dose (each Cycle is of 28 days)","title":"Part A: Multiple Dose: Area Under Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) of M3258","type":"SECONDARY"}